Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

NCT07300488 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

DRUG: Pracytarabine
DRUG: regorafenib

Sponsor

Xi'an Xintong Pharmaceutical Research Co.,Ltd.